A post hoc analysis of the FUTURE 2 trial has shown that patients treated with secukinumab for psoriatic arthritis (PsA) achieved higher rates of remission or low disease activity (LDA) defined by the Psoriatic Arthritis Disease Activity Score (PASDAS), according to research published in Arthritis Research & Therapy. Significantly greater improvements in health related-quality of life (HRQoL), physical function, work productivity, and activity impairments were associated with PASDAS remission or LDA.
Researchers from the phase 3 multicenter randomized control FUTURE 2 trial (ClinicalTrials.gov identifier: NCT01752634) conducted a post hoc analysis to determine the ability of patients treated with secukinumab to achieve remission or LDA assessed at 16, 52, and 104 weeks. The analysis also identified the relationship of PASDAS states with patient-reported outcomes (PROs). PASDAS cut-off scores identified states of disease activity, for remission (PASDAS score ≤1.9), LDA (PASDAS score between 1.9 and 3.2), moderate disease activity (PASDAS score ≥3.2 and <5.4), and high disease activity (PASDAS score ≥5.4).
At 16 weeks, remission and LDA were achieved in 15.6% and 22.9% of patients who were treated with 300 mg secukinumab and in 15.2% and 19.2% of patients receiving 150 mg secukinumab, compared with 2.3% and 13.8% of patients receiving placebo. The majority of patients meeting either PASDAS remission or LDA either maintained or improved their status over time, as revealed in shift analysis from 16 to 52 weeks and from 16 to 104 weeks.
The use of PASDAS to measure disease activity in PsA presents potential limitations because it does not measure for axial involvement and patient pain.
The researchers concluded that “secukinumab-treated patients achieved higher PASDAS-defined remissions or LDA compared with placebo at week 16, which were sustained through 2 years.”
This study was supported by Novartis Pharma AG. Please see the original source for a full list of disclosures.
Coates LC, Gladman DD, Nash P, et al. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther. 2018;20(1)272.